ScholarLens Back to search
2021•Canadian Medical Association JournalOpen access

Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)

Kevin Brown, Matthew D. Seftel, Kevin Anthony Hay

Open full text 4 citations

Abstract

KEY POINTS Cellular immunotherapy is a novel therapy where the body’s own immune cells are harnessed for their anticancer effect. One of the most exciting of these approaches is chimeric antigen receptor T-cell therapy (CAR-T). This therapy is now standard of care for relapsed or refractory B-cell

Open-access reader

About this research paper

What this paper is about

KEY POINTS Cellular immunotherapy is a novel therapy where the body’s own immune cells are harnessed for their anticancer effect. One of the most exciting of these approaches is chimeric antigen receptor T-cell therapy (CAR-T). This therapy is now standard of care for relapsed or refractory B-cell

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

KEY POINTS Cellular immunotherapy is a novel therapy where the body’s own immune cells are harnessed for their anticancer effect. One of the most exciting of these approaches is chimeric antigen receptor T-cell therapy (CAR-T). This therapy is now standard of care for relapsed or refractory B-cell

Key concepts: Chimeric antigen receptor, Immunotherapy, Cell therapy, Medicine, Cancer immunotherapy, Immunology, Antigen, T cell

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T) — Research Paper | ScholarLens